Coherus Oncology, Inc. - Common Stock (CHRS)

CUSIP: 19249H103

Q1 2018 13F Holders as of 31 Mar 2018

Holder snapshot 7 signals
Share change
+2,944,282
Put/Call ratio
50%
SEC-reported price per share
$11.05
Indexed holders
102
Value change
+$32,866,184
Number of buys
60
Open additional details 1 more signal available
Number of sells
39
Security identity Names, identifiers, and filing context for this profile. 1 source field
Shares outstanding
154,050,897

Security key

19249H103

Report period

Q1 2018

Indexed institutions

102

Top holders

10

Ownership snapshot

Top reported holders of CHRS - Coherus Oncology, Inc. - Common Stock (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.

Comparable stake leader
WELLINGTON MANAGEMENT GRO...
Disclosed value leader
WELLINGTON MANAGEMENT GRO...
Comparable rows
0/15
Latest evidence
31 Dec 2017
13F Highest disclosed value: $63,883,000 15 rows are not safely comparable across share classes. Showing 1-6 of 15 holder rows.

Quick read

WELLINGTON MANAGEMENT GROUP LLP has the largest disclosed position value at $63.88M.

0 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.

Open SEC evidence Opens WELLINGTON MANAGEMENT GROUP LLP's linked filing trail.
Disclosed position value Top 5
WELLINGTON MANAGEMENT GROUP LLP $63.88M
FMR LLC $58.82M
Temasek Holdings (Private) Ltd $57.69M
BlackRock Finance, Inc. $28.15M
Kohlberg Kravis Roberts & Co. L.P. $26.88M

Value bars compare disclosed positions; verify each figure against the linked filing evidence.

Detailed SEC evidence table Showing 1-6 of 15 holder rows
Holder Evidence Ownership % Position 12M Net Δ As of
WELLINGTON MANAGEMENT GROUP LLP
13F
Company
13F
—
denominator unverified
$63,883,000
7,259,398 shares
— 31 Dec 2017
FMR LLC
13F
Company
13F
—
denominator unverified
$58,820,000
6,684,166 shares
— 31 Dec 2017
Temasek Holdings (Private) Ltd
13F
Company
13F
—
denominator unverified
$57,694,000
6,556,116 shares
— 31 Dec 2017
BlackRock Finance, Inc.
13F
Company
13F
—
denominator unverified
$28,149,000
3,198,726 shares
— 31 Dec 2017
Kohlberg Kravis Roberts & Co. L.P.
13F
Company
13F
—
denominator unverified
$26,884,000
3,055,055 shares
— 31 Dec 2017
STATE STREET CORP
13F
Company
13F
—
denominator unverified
$18,519,000
2,104,510 shares
— 31 Dec 2017
How to read this table

Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

13F holder rows

Institutional holders as of Q1 2018

Investor-level positions for this CUSIP, loaded as an interactive table.

Indexed institutions
102
Shares
55,290,055
Indexed holders
102
Investor Option Weight % Change % SEC-reported value * Price Shares Share Change Activity Report Period

* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.

Reported share positions only; options and principal amounts are excluded. Missing manager disclosures are unavailable, not zero. A missing position becomes zero only when complete coverage is verified for both snapshots. Counts describe the indexed universe; the comparison may cover a smaller set.

Compare Q1 2018 vs Q4 2017 Across Filers

Q4 2017 indexed holders
92
Q1 2018 indexed holders
102
Indexed holder difference
10
Investor Q4 2017 Shares Q1 2018 Shares Share Diff Share Chg % Q4 2017 value Q1 2018 value Value change Value Chg %

Trend: the last eight indexed quarters, including the selected comparison periods.

Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .